O Fernández, X Montalbán, E Agüera, Y Aladro, A Alonso, R Arroyo, L Brieva, C Calles, L Costa-Frossard, S Eichau, J M García-Domínguez, M A Hernández, L Landete, M Llaneza, S Llufriu, J E Meca-Lallana, V Meca-Lallana, E Moral, J M Prieto, Ll Ramió-Torrentà, N Téllez, L Romero-Pinel, A Vilaseca, A Rodríguez-Antigüedad
{"title":"[第十六届欧洲毒理学和分子生物学大会后的会议：2023 年欧洲毒理学和分子生物学大会（II）新进展回顾]。","authors":"O Fernández, X Montalbán, E Agüera, Y Aladro, A Alonso, R Arroyo, L Brieva, C Calles, L Costa-Frossard, S Eichau, J M García-Domínguez, M A Hernández, L Landete, M Llaneza, S Llufriu, J E Meca-Lallana, V Meca-Lallana, E Moral, J M Prieto, Ll Ramió-Torrentà, N Téllez, L Romero-Pinel, A Vilaseca, A Rodríguez-Antigüedad","doi":"10.33588/rn.7902.2024174","DOIUrl":null,"url":null,"abstract":"<p><p>The XVI Post-ECTRIMS meeting was held in Seville on 20 and 21 October 2023, where expert neurologists in multiple sclerosis (MS) summarised the main new developments presented at the ECTRIMS 2023 congress, which took place in Milan from 11 to 13 October. The aim of this article is to summarise the content presented at the Post-ECTRIMS Meeting, in an article in two parts. This second part covers the health of women and elderly MS patients, new trends in the treatment of cognitive impairment, focusing particularly on meditation, neuroeducation and cognitive rehabilitation, and introduces the concept of fatigability, which has been used to a limited extent in MS. The key role of digitalization and artificial intelligence in the theoretically near future is subject to debate, along with the potential these technologies can offer. The most recent research on the various treatment algorithms and their efficacy and safety in the management of the disease is reviewed. Finally, the most relevant data for cladribine and evobrutinib are presented, as well as future therapeutic strategies currently being investigated.</p>","PeriodicalId":21281,"journal":{"name":"Revista de neurologia","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11469095/pdf/","citationCount":"0","resultStr":"{\"title\":\"[XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (II)].\",\"authors\":\"O Fernández, X Montalbán, E Agüera, Y Aladro, A Alonso, R Arroyo, L Brieva, C Calles, L Costa-Frossard, S Eichau, J M García-Domínguez, M A Hernández, L Landete, M Llaneza, S Llufriu, J E Meca-Lallana, V Meca-Lallana, E Moral, J M Prieto, Ll Ramió-Torrentà, N Téllez, L Romero-Pinel, A Vilaseca, A Rodríguez-Antigüedad\",\"doi\":\"10.33588/rn.7902.2024174\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The XVI Post-ECTRIMS meeting was held in Seville on 20 and 21 October 2023, where expert neurologists in multiple sclerosis (MS) summarised the main new developments presented at the ECTRIMS 2023 congress, which took place in Milan from 11 to 13 October. The aim of this article is to summarise the content presented at the Post-ECTRIMS Meeting, in an article in two parts. This second part covers the health of women and elderly MS patients, new trends in the treatment of cognitive impairment, focusing particularly on meditation, neuroeducation and cognitive rehabilitation, and introduces the concept of fatigability, which has been used to a limited extent in MS. The key role of digitalization and artificial intelligence in the theoretically near future is subject to debate, along with the potential these technologies can offer. The most recent research on the various treatment algorithms and their efficacy and safety in the management of the disease is reviewed. Finally, the most relevant data for cladribine and evobrutinib are presented, as well as future therapeutic strategies currently being investigated.</p>\",\"PeriodicalId\":21281,\"journal\":{\"name\":\"Revista de neurologia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2024-07-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11469095/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Revista de neurologia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.33588/rn.7902.2024174\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista de neurologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.33588/rn.7902.2024174","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
[XVI Post-ECTRIMS Meeting: review of the new developments presented at the 2023 ECTRIMS Congress (II)].
The XVI Post-ECTRIMS meeting was held in Seville on 20 and 21 October 2023, where expert neurologists in multiple sclerosis (MS) summarised the main new developments presented at the ECTRIMS 2023 congress, which took place in Milan from 11 to 13 October. The aim of this article is to summarise the content presented at the Post-ECTRIMS Meeting, in an article in two parts. This second part covers the health of women and elderly MS patients, new trends in the treatment of cognitive impairment, focusing particularly on meditation, neuroeducation and cognitive rehabilitation, and introduces the concept of fatigability, which has been used to a limited extent in MS. The key role of digitalization and artificial intelligence in the theoretically near future is subject to debate, along with the potential these technologies can offer. The most recent research on the various treatment algorithms and their efficacy and safety in the management of the disease is reviewed. Finally, the most relevant data for cladribine and evobrutinib are presented, as well as future therapeutic strategies currently being investigated.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
